CN117586432B - Preparation method and application of zinc hyaluronate - Google Patents
Preparation method and application of zinc hyaluronate Download PDFInfo
- Publication number
- CN117586432B CN117586432B CN202311480051.4A CN202311480051A CN117586432B CN 117586432 B CN117586432 B CN 117586432B CN 202311480051 A CN202311480051 A CN 202311480051A CN 117586432 B CN117586432 B CN 117586432B
- Authority
- CN
- China
- Prior art keywords
- zinc
- hyaluronate
- stirring
- aqueous solution
- zinc chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method and application of zinc hyaluronate, belonging to the technical field of biological medicine, the preparation method comprises the steps of mixing sodium hyaluronate with deionized water, and stirring to obtain sodium hyaluronate solution; the method comprises the steps of dissolving zinc chloride in deionized water, stirring to obtain zinc chloride aqueous solution, mixing the zinc chloride aqueous solution with sodium hyaluronate solution, stirring, adding hydrochloric acid solution to adjust the pH to 5-5.5, heating to 40-45 ℃, stirring, adding an accelerator, adding hydrochloric acid solution to continuously adjust the pH to 4-4.5, continuously stirring, filtering, adding absolute ethyl alcohol into filtrate for precipitation until no condensation occurs, washing the precipitate with the absolute ethyl alcohol, dehydrating, granulating, and vacuum drying.
Description
Technical Field
The invention relates to the technical field of biological medicine, in particular to a preparation method and application of zinc hyaluronate.
Background
Sodium hyaluronate, also known as sodium hyaluronate, is a polysaccharide formed by repeatedly connecting glucuronic acid and glucosamine disaccharide units, is one of the main components forming the extracellular matrix of skin, has extremely high hydrophilicity and viscoelasticity, and is known as an ideal natural moisturizing factor. When applied to the skin surface, the sodium hyaluronate not only has the moisturizing and sliding effects, but also has the physiological effects of nutrition, repair, injury prevention and the like, is a nontoxic, nonimmunogenic and noninflammatory biological material, and has good biodegradability and compatibility. Zinc is an indispensable trace element of human body, and plays a role in sexual development, sexual function and generation of germ cells of the body. Zinc is an important component of more than 200 enzymes in the body, is related to brain development and intelligence, has the functions of promoting lymphocyte proliferation and activity, and is very useful for maintaining normal epithelial and mucosal tissues, preventing bacterial and viral invasion, promoting wound healing, reducing skin lesions such as acne, correcting gustatory failure and the like.
The zinc hyaluronate is a zinc salt of hyaluronic acid, and a compound generated by the reaction of sodium hyaluronate and a zinc salt reagent has the biological activity of sodium hyaluronate and zinc element and has good synergistic effect. The zinc hyaluronate can be used as health food such as capsule or solution, and can be used for providing zinc element for human body by oral administration and smearing, and can greatly improve absorption of hyaluronic acid in human body, and also can be used for promoting cornea injury healing, diabetic foot wound healing, antimicrobial activity, antioxidant and oxidation injury resisting effects, treating burn, and treating peptic ulcer.
The current method for preparing zinc hyaluronate is mainly an ion replacement method, and the ion replacement method is mainly divided into two types. The first is an ion exchange method under the state of solution, which is to dissolve the hyaluronic acid and then to put the hyaluronic acid on an ion exchange column to convert Na-HA into Zn-HA, then to deposit the Zn-HA by ethanol, and to dry the Zn-HA by dehydration. The second is the ion exchange method under the solid state, firstly, the zinc salt is dissolved in alcohol-water solution with a certain concentration, na-HA powder is added, and the substitution reaction is completed under the solid state.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides the preparation method and the application of the zinc hyaluronate, which have the advantages of mild reaction process, simple separation and purification steps, low production cost, suitability for industrial production, high zinc content, low sodium content, quick dissolution in solution and high light transmittance of the prepared zinc hyaluronate.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
The preparation method of zinc hyaluronate comprises mixing sodium hyaluronate with deionized water, stirring at 100-300rpm at room temperature until completely dissolving to obtain sodium hyaluronate solution, dissolving zinc chloride in deionized water, stirring uniformly to obtain zinc chloride aqueous solution, mixing zinc chloride aqueous solution with sodium hyaluronate solution, stirring at 100-300rpm at room temperature for 10-30min, adding hydrochloric acid solution to adjust pH to 5-5.5, heating to 40-45 ℃, stirring for 3-4h, adding promoter, adding hydrochloric acid solution to continuously adjust pH to 4-4.5, stirring for 2-3h, filtering, adding absolute ethanol into filtrate for precipitation until no aggregation occurs, washing precipitate with 2-3 times of absolute ethanol, dehydrating, granulating, and vacuum drying the obtained granule at 50-60 ℃ for 7-8h to obtain zinc hyaluronate granule;
the molecular weight of sodium hyaluronate in the sodium hyaluronate solution is 400-1000kDa;
The mass volume ratio of the sodium hyaluronate to the deionized water in the sodium hyaluronate solution is 10-50g:200-2000mL;
The mass volume ratio of zinc chloride to deionized water in the zinc chloride aqueous solution is 1.7-13.58g:20-50mL;
The mass ratio of the sodium hyaluronate in the sodium hyaluronate solution to the zinc chloride in the zinc chloride aqueous solution is 10-50:1.7-13.58:0.6-0.7;
the mass fractions of the hydrochloric acid solution are 18-22%;
The adding speed of the absolute ethyl alcohol is 8-10g/min;
The preparation method of the accelerator comprises the steps of adding zeolite powder into a first zinc chloride aqueous solution, stirring at a stirring speed of 60-120rpm for 40-60min at 40-60 ℃, filtering, washing filter residues with deionized water for 2-3 times, mixing the washed filter residues with the sodium alginate aqueous solution, stirring at a stirring speed of 60-120rpm for 40-60min at 30-50 ℃, filtering, washing the filter residues with deionized water for 2-3 times, mixing the washed filter residues with a second zinc chloride aqueous solution, stirring at a stirring speed of 60-120rpm for 40-60min at 40-60 ℃, filtering, washing the filter residues with deionized water for 2-3 times, and vacuum drying at 60-70 ℃ for 4-5h to obtain the accelerator;
In the preparation of the accelerator, the mass fraction of the first zinc chloride aqueous solution is 9-10%;
The mass fraction of the sodium alginate aqueous solution is 2.5-3%;
The mass fraction of the second zinc chloride aqueous solution is 7-8%;
the mass ratio of the zeolite powder to the first zinc chloride aqueous solution to the sodium alginate aqueous solution to the second zinc chloride aqueous solution is 10-12:120-130:130-150:90-100;
the particle size of the zeolite powder is 80-120 meshes.
Use of zinc hyaluronate prepared by the aforementioned preparation method is provided.
Compared with the prior art, the invention has the beneficial effects that:
(1) The preparation method of the zinc hyaluronate can improve the zinc content in the zinc hyaluronate, reduce the sodium content, and the zinc content in the prepared zinc hyaluronate is 9.95-10.22%, the sodium content is 0.16-0.21%, and the light transmittance is 99.4-99.9%;
(2) According to the preparation method of the zinc hyaluronate, disclosed by the invention, the zinc hyaluronate is prepared into the zinc hyaluronate by adopting a granulating process, so that small particle dust is prevented from being generated, and the zinc hyaluronate can be rapidly dispersed and dissolved in liquid, so that the time and the cost are saved;
(3) According to the preparation method of the zinc hyaluronate, the prepared zinc hyaluronate can promote cell proliferation, improve the protein content in cells, reduce the lipid content in cells and achieve the effect of tightening.
Detailed Description
Specific embodiments of the present invention will now be described in order to provide a clearer understanding of the technical features, objects and effects of the present invention.
Example 1
A preparation method of zinc hyaluronate specifically comprises the following steps:
Adding 10g of sodium hyaluronate with the molecular weight of 1000kDa and 2000mL of deionized water into a 5000mL reaction bottle, stirring at the stirring speed of 100rpm at room temperature until the sodium hyaluronate is completely dissolved to obtain sodium hyaluronate solution, dissolving 1.7g of zinc chloride into 20mL of deionized water, uniformly stirring, adding into a 5000mL reaction bottle to be mixed with the sodium hyaluronate solution, stirring at the stirring speed of 100rpm at room temperature for 10min, adding a hydrochloric acid solution with the mass fraction of 18% to adjust the pH value to 5, then heating to 40 ℃, stirring for 3h, then adding 0.6g of an accelerator, adding a hydrochloric acid solution with the mass fraction of 18% to continuously adjust the pH value to 4, continuously stirring for 3h, filtering, slowly adding absolute ethanol into the filtrate to precipitate, controlling the adding speed to be 8g/min until the precipitate is not generated, washing the precipitate for 2 times by using absolute ethanol with the precipitation volume, granulating after dehydration, and then placing the obtained granules into 50 ℃ for vacuum drying for 8h to obtain 10.5g of zinc hyaluronate granules;
The preparation method of the accelerator comprises the steps of adding 10g of zeolite powder into 120g of zinc chloride aqueous solution with the mass fraction of 9%, stirring at the stirring speed of 60rpm for 40min at 40 ℃, filtering, washing filter residues with deionized water for 2 times, mixing the washed filter residues with 130g of sodium alginate aqueous solution with the mass fraction of 2.5%, stirring at the stirring speed of 60rpm for 40min at 30 ℃, filtering, washing the filter residues with deionized water for 2 times, mixing the washed filter residues with 90g of zinc chloride aqueous solution with the mass fraction of 7%, stirring at the stirring speed of 60rpm for 40min at 40 ℃, filtering, washing the filter residues with deionized water for 2 times, and drying at 70 ℃ to obtain the accelerator;
the grain diameter of the zeolite powder is 80 meshes;
The detection shows that the zinc content in the zinc hyaluronate particle product is 9.95%, the sodium content is 0.21%, the molecular weight is 740kDa, and the light transmittance is 99.4%.
Example 2
A preparation method of zinc hyaluronate specifically comprises the following steps:
Adding 10g of sodium hyaluronate with the molecular weight of 400kDa and 200mL of deionized water into a 5000mL reaction bottle, stirring at the stirring speed of 200rpm at room temperature until the sodium hyaluronate is completely dissolved to obtain sodium hyaluronate solution, dissolving 2.7g of zinc chloride into 20mL of deionized water, uniformly stirring, adding into a 5000mL reaction bottle to be mixed with the sodium hyaluronate solution, stirring at the stirring speed of 200rpm at room temperature for 20min, adding a hydrochloric acid solution with the mass fraction of 20% to adjust the pH value to 5.2, heating to 42 ℃, stirring for 3.5h, adding 0.6g of an accelerator, adding a hydrochloric acid solution with the mass fraction of 20% to continuously adjust the pH value to 4.2, continuously stirring for 2.5h, filtering, slowly adding absolute ethanol into the filtrate to perform precipitation, controlling the adding speed to be 9g/min, washing the precipitation with absolute ethanol with the volume of 2 times until no aggregation is generated, granulating, then placing the obtained granules into 55 ℃ to be dried under vacuum for 7.5h, and obtaining 11.3g of zinc hyaluronate granules;
The preparation method of the accelerator comprises the steps of adding 11g of zeolite powder into 125g of zinc chloride aqueous solution with the mass fraction of 9.5%, stirring for 50min at the stirring speed of 100rpm at 50 ℃, filtering, washing filter residues with deionized water for 2 times, mixing the washed filter residues with 140g of sodium alginate aqueous solution with the mass fraction of 2.8%, stirring for 50min at the stirring speed of 100rpm at 40 ℃, filtering, washing the filter residues with deionized water for 2 times, mixing the washed filter residues with 95g of zinc chloride aqueous solution with the mass fraction of 7.5%, stirring for 50min at the stirring speed of 100rpm at 50 ℃, filtering, washing the filter residues with deionized water for 2 times, and drying at 75 ℃ to obtain the accelerator;
The particle size of the zeolite powder is 100 meshes;
The detection shows that the zinc content in the zinc hyaluronate particle product is 9.80%, the sodium content is 0.16%, the molecular weight is 290kDa, and the light transmittance is 99.9%.
Example 3
A preparation method of zinc hyaluronate specifically comprises the following steps:
adding 50g of sodium hyaluronate with the molecular weight of 400kDa and 2000mL of deionized water into a 5000mL reaction bottle, stirring at the stirring speed of 300rpm at room temperature until the sodium hyaluronate is completely dissolved to obtain sodium hyaluronate solution, adding 13.58g of zinc chloride into 50mL of deionized water, uniformly stirring, adding into a 5000mL reaction bottle to be mixed with the sodium hyaluronate solution, stirring at the stirring speed of 300rpm at room temperature for 30min, adding a hydrochloric acid solution with the mass fraction of 22% to adjust the pH value to 5.5, then heating to 45 ℃, stirring for 4h, then adding 0.7g of an accelerator, adding a hydrochloric acid solution with the mass fraction of 22% to continuously adjust the pH value to 4.5, continuously stirring for 2h, filtering, slowly adding absolute ethanol into filtrate to precipitate, controlling the adding speed to be 10g/min until the absolute ethanol with the precipitation volume of 3 times is not generated, then carrying out dehydration, granulating, and then placing the obtained granules into 60 ℃ to be dried in vacuum for 7h to obtain 56.4g of zinc hyaluronate particles;
The preparation method of the accelerator comprises the steps of adding 12g of zeolite powder into 130g of zinc chloride aqueous solution with the mass fraction of 10%, stirring at the stirring speed of 120rpm for 60min at 60 ℃, filtering, washing filter residues with deionized water for 3 times, mixing the washed filter residues with 150g of sodium alginate aqueous solution with the mass fraction of 3%, stirring at the stirring speed of 120rpm for 60min at 50 ℃, filtering, washing the filter residues with deionized water for 3 times, mixing the washed filter residues with 100g of zinc chloride aqueous solution with the mass fraction of 8%, stirring at the stirring speed of 120rpm for 60min at 60 ℃, filtering, washing the filter residues with deionized water for 3 times, and drying at 80 ℃ to obtain the accelerator;
the grain diameter of the zeolite powder is 120 meshes;
The detection shows that the zinc content in the zinc hyaluronate particle product is 10.22%, the sodium content is 0.17%, the molecular weight is 260kDa, and the light transmittance is 99.5%.
Comparative example 1
The same preparation method of the zinc hyaluronate as in example 3 is adopted, except that the step of adding the hydrochloric acid solution with the mass fraction of 22% to adjust the pH to 5.5 and the step of adding the hydrochloric acid solution with the mass fraction of 22% to continuously adjust the pH to 4.5 are omitted, namely, the pH is adjusted without adding the hydrochloric acid solution in the reaction;
The zinc content in the obtained zinc hyaluronate particle product is 7.20%, the sodium content is 2.25%, the molecular weight is 280kDa, and the light transmittance is 99.5%.
Comparative example 2
The same preparation method of zinc hyaluronate as in example 3 was employed, except that the addition of the promoter was omitted from the reaction;
The zinc content in the obtained zinc hyaluronate particle product is 7.94%, the sodium content is 3.72%, the molecular weight is 270kDa, and the light transmittance is 99.1%.
From the test results of examples 1 to 3 and comparative examples 1 to 2, it can be seen that by controlling the pH in stages, the decrease in the positive reaction efficiency, the decrease in the zinc content and the increase in the sodium content caused by the occurrence of the zinc hydrolysis side reaction can be avoided;
The accelerator takes zeolite powder as an inner core, sodium alginate and zinc ions are added to complex after the zeolite powder is adsorbed, so as to form microspheres to be wrapped on the surface of the zeolite powder, and finally, the microspheres are treated by the zinc ions, so that the sodium alginate can be completely complexed, and in the adding reaction, a large specific surface area can be provided for the reaction, thereby promoting the reaction, and in addition, part of sodium ions can be combined to release the zinc ions, thereby playing the roles of improving the zinc content in the zinc hyaluronate particle product and reducing the sodium content.
Test examples
The zinc hyaluronate particle product of example 3 was subjected to a tightening efficacy test, the specific efficacy test method being as follows:
Test for promoting cell proliferation based on fibroblasts, using fibroblasts supplied by Guangdong Boxi biotechnology Co., ltd., cell viability and cell proliferation were measured by MTT method, the zinc hyaluronate particle product prepared in example 3 was used as a test sample, the concentration gradient of the test sample was set to 5. Mu.g/mL, 3. Mu.g/mL, 1. Mu.g/mL, 2% NBS was used as a blank control, 10% NBS was used as a positive control, and MTT measurement was performed at 24h, 48h, 72h time gradients, respectively.
Fibroblasts were inoculated into 96-well plates at a cell inoculum size of 3.5X10 3 cells/well, incubated overnight in an incubator (37 ℃ C., 5% CO 2), and when the plating rate of the cells in the 96-well plates reached 30%, grouped administration (i.e., zinc hyaluronate particle product prepared in example 3) was performed, and the results were recorded in the incubator for 24 hours, 48 hours, and 72 hours, respectively;
After incubation of the cells for 24h, the supernatant was discarded, MTT working solution (0.5 mg/mL, as prepared) was added, incubated at 37℃for 4h in the absence of light, after incubation, the supernatant was discarded, 150. Mu.L of DMSO was added per well, and the OD was read at 490 nm. Similarly, after 48h and 72h, equivalent MTT assays were performed.
The test results show that, compared with the blank control group, the zinc hyaluronate particle product prepared in the embodiment 3 has a remarkable promotion effect on proliferation of fibroblasts after 48 hours of administration, is promoted to 10.85%, has no remarkable promotion effect on proliferation of Cheng Wei cells after 24 hours and 72 hours of administration, has a remarkable promotion effect on proliferation of fibroblasts after 48 hours and 72 hours of administration, has no remarkable promotion effect on proliferation of fibroblasts after 24 hours of administration, has a promotion rate of 12.71% and 4.43% respectively, and has a remarkable promotion effect on proliferation of fibroblasts after 48 hours and 72 hours of administration at a degree of 5ug/mL, and has a remarkable promotion effect on proliferation of fibroblasts after 16.28% and 5.43% respectively.
Through the above test, it is demonstrated that the zinc hyaluronate granule product prepared in example 3 promotes cell proliferation at the corresponding test concentration, and achieves the effect of tightening skin.
Protein content improvement test the cells used in the test are fibroblasts, which are provided by Guangdong Boxi biotechnology Co., ltd. By detecting the change of the protein content of type I Collagen (Collagen I), the compaction efficacy of the sample to be tested is evaluated by the following specific method:
Sample solutions were prepared from the zinc hyaluronate particle products prepared in example 3, the zinc hyaluronate concentrations were controlled to be 125 μg/mL, 12.5 μg/mL, and 1.25 μg/mL, and when the cell plating rate in the 6-well plate reached 60%, the 6-well plate was subjected to group administration with 2mL of each well, 3 duplicate wells were provided for each group, and after the administration was completed, the 6-well plate was placed in an incubator (37 ℃ C., 5% CO) for 24 hours, and then the cell culture supernatant was collected in an EP tube, frozen and stored in a refrigerator at-80 ℃ C., and tested according to the instructions of the Collagen I ELISA kit.
The test results show that, compared with the blank group, the zinc hyaluronate particle product prepared in example 3 has significantly increased Collagen I content at the concentration of 125 μg/mL, 12.5 μg/mL and 1.25 μg/mL, and the improvement rates are 13.91%, 16.12% and 18.44%, respectively, and it is considered that the zinc hyaluronate particle product prepared in example 3 has the effect of skin tightening by improving Collagen I protein content at the corresponding test concentrations.
Similarly, the same tests were conducted on the above-mentioned example 1, example 2 and comparative examples 1 and 2 at a concentration of 1.25. Mu.g/mL, and the Collagen I elevation rates were 16.8%, 17.5%, 11.68% and 12.75%, respectively.
Oil control efficacy test based on sebaceous cells, the oil control efficacy of the zinc hyaluronate granule product prepared in example 3 was evaluated by detecting the lipid drop content of sebaceous cells after the zinc hyaluronate granule product prepared in example 3 was acted, and the specific test is as follows:
The cells used were sebaceous gland cells, which were supplied by Guangdong Boxi biotechnology Co., ltd, sample solutions were prepared from the zinc hyaluronate granule products prepared in example 3, the zinc hyaluronate concentrations were controlled to be 125ug/mL, 25ug/mL, 5ug/mL, SZ95 cells were inoculated to 24 well plates at an inoculation density of 3.5X10 4 cells/well, incubated overnight in an incubator (37 ℃ C., 5% CO 2), and when the cell plating rate in the 24 well plates reached 50%, group dosing was performed, 1mL of each well was added, 3 compound wells were provided per group, and after the dosing was completed, the 24 well plates were placed in the incubator (37 ℃ C., 5% CO 2) for 24 hours, and were detected by the oil red O staining method. And (3) photographing and observing by a fluorescence microscope, detecting at Ex of 450-500 nm and Em of 515-560 nm, and photographing and observing under a 200-fold mirror.
The test results show that the zinc hyaluronate particle product prepared in example 3 has significantly reduced lipid content at concentrations of 125 mug/mL, 25 mug/mL and 5 mug/mL, which indicates that the sample can reduce lipid drop synthesis at the detection concentration, and the inhibition rates are 11.18%, 8.9% and 8.7%, respectively.
Similarly, the inhibition ratios of example 1, example 3, comparative example 1 and comparative example 2 were 10.87%, 11.01%, 7.12% and 7.87%, respectively, by the same test at a concentration of 125 ug/mL.
From the above results, it can be seen that the zinc hyaluronate prepared in examples 1 to 3 can promote collagen production and achieve a certain tightening effect on the skin. The zinc hyaluronate prepared in the embodiment 3 has a promoting effect on proliferation of fibroblasts within a certain period of time under a certain test concentration, achieves the effect of tightening skin by proliferating the fibroblasts, does not show obvious cytotoxicity within a concentration range of 0.125mg/mL, has a remarkable increase of collagen content in the fibroblasts by adding the zinc hyaluronate prepared in the embodiment 1-3 within a certain concentration range, has a high lifting rate, promotes generation of collagen, achieves the aim of tightening skin, and can effectively inhibit lipid drop synthesis, reduce lipid secretion and has an effect of controlling oil on skin under different concentrations.
The percentages used in the present invention are mass percentages unless otherwise indicated.
It should be noted that the above-mentioned embodiments are merely preferred embodiments of the present invention, and the present invention is not limited thereto, but may be modified or substituted for some of the technical features thereof by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. A preparation method of zinc hyaluronate is characterized by comprising the steps of mixing sodium hyaluronate with deionized water, stirring to obtain sodium hyaluronate solution, dissolving zinc chloride in the deionized water, stirring to obtain zinc chloride aqueous solution, mixing the zinc chloride aqueous solution with the sodium hyaluronate solution, stirring, adding hydrochloric acid solution to adjust the pH to 5-5.5, then heating to 40-45 ℃, stirring, adding an accelerator, adding hydrochloric acid solution to continuously adjust the pH to 4-4.5, continuously stirring, filtering, adding absolute ethyl alcohol into filtrate for precipitation, washing the precipitate with absolute ethyl alcohol until no aggregation occurs, dehydrating, granulating, and vacuum drying to obtain zinc hyaluronate particle products;
The preparation method of the accelerator comprises the steps of adding zeolite powder into a first zinc chloride aqueous solution, stirring at 40-60 ℃, filtering, cleaning filter residues, mixing the cleaned filter residues with a sodium alginate aqueous solution, stirring at 30-50 ℃, filtering, cleaning the filter residues, then stirring the cleaned filter residues with a second zinc chloride aqueous solution at 40-60 ℃, filtering, cleaning the filter residues, and then drying in vacuum to obtain the accelerator.
2. The method for preparing zinc hyaluronate according to claim 1, wherein the molecular weight of sodium hyaluronate in the sodium hyaluronate solution is 400KDa-1000KDa.
3. The preparation method of the zinc hyaluronate according to claim 1, wherein the mass-volume ratio of the sodium hyaluronate to the deionized water in the sodium hyaluronate solution is 10-50g:200-2000mL;
The mass volume ratio of zinc chloride to deionized water in the zinc chloride aqueous solution is 1.7-13.58g:20-50mL;
the mass ratio of the sodium hyaluronate in the sodium hyaluronate solution to the zinc chloride in the zinc chloride aqueous solution to the accelerator is 10-50:1.7-13.58:0.6-0.7.
4. The preparation method of the zinc hyaluronate according to claim 1, wherein the mass fractions of the hydrochloric acid solution are 18-22%;
the adding speed of the absolute ethyl alcohol is 8-10g/min.
5. The method for producing zinc hyaluronate according to claim 1, wherein in the production of the accelerator, the mass fraction of the first zinc chloride aqueous solution is 9 to 10%;
The mass fraction of the sodium alginate aqueous solution is 2.5-3%;
the mass fraction of the second zinc chloride aqueous solution is 7-8%.
6. The method for preparing zinc hyaluronate according to claim 1, wherein in the preparation of the accelerator, the mass ratio of zeolite powder, the first zinc chloride aqueous solution, the sodium alginate aqueous solution and the second zinc chloride aqueous solution is 10-12:120-130:130-150:90-100;
the particle size of the zeolite powder is 80-120 meshes.
7. Use of zinc hyaluronate prepared by the preparation method of any one of claims 1 to 6 for preparing a skin tightening product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311480051.4A CN117586432B (en) | 2023-11-08 | 2023-11-08 | Preparation method and application of zinc hyaluronate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311480051.4A CN117586432B (en) | 2023-11-08 | 2023-11-08 | Preparation method and application of zinc hyaluronate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117586432A CN117586432A (en) | 2024-02-23 |
| CN117586432B true CN117586432B (en) | 2025-02-18 |
Family
ID=89914238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311480051.4A Active CN117586432B (en) | 2023-11-08 | 2023-11-08 | Preparation method and application of zinc hyaluronate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117586432B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647100A (en) * | 2020-07-14 | 2020-09-11 | 山东华熙海御生物医药有限公司 | Preparation method of high molecular weight zinc hyaluronate |
| CN116948054A (en) * | 2022-04-20 | 2023-10-27 | 华熙生物科技股份有限公司 | A kind of preparation method and application of zinc hyaluronate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070017374A (en) * | 2004-05-27 | 2007-02-09 | 노보자임스 바이오폴리머 에이/에스 | Rapidly dissolving dry hyaluronic acid product |
| CN100355790C (en) * | 2005-11-04 | 2007-12-19 | 山东福瑞达生物化工有限公司 | Method for preparing transparent zinc hyaluronic acid |
| EP2559708B1 (en) * | 2010-04-14 | 2018-06-20 | Kewpie Corporation | Process for producing zinc hyaluronate, process for producing cosmetic containing zinc hyaluronate, zinc hyaluronate and process for producing the same |
| RU2710074C1 (en) * | 2019-10-02 | 2019-12-24 | Общество с ограниченной ответственностью "МедикалСайнс" | Hydrogel water-soluble composition based on hyaluronic acid and polyvalent metal ions and a method for production thereof |
-
2023
- 2023-11-08 CN CN202311480051.4A patent/CN117586432B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647100A (en) * | 2020-07-14 | 2020-09-11 | 山东华熙海御生物医药有限公司 | Preparation method of high molecular weight zinc hyaluronate |
| CN116948054A (en) * | 2022-04-20 | 2023-10-27 | 华熙生物科技股份有限公司 | A kind of preparation method and application of zinc hyaluronate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117586432A (en) | 2024-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100360035C (en) | Preparation method of chitosan/zinc composite antibacterial agent | |
| CN100360036C (en) | Preparation method of chitosan/metal copper composite antibacterial agent | |
| CN108752501B (en) | A kind of chitosan quaternary ammonium salt containing organic acid salt and its preparation method and application | |
| JP7685140B2 (en) | Use of hyaluronic acid or its salt and/or trehalose in stabilizing ergothioneine, and ergothioneine composition containing hyaluronic acid or its salt and/or trehalose | |
| CN108324731B (en) | Preparation method and application of biological polysaccharide granules for improving antioxidant activity and enhancing bacteriostatic effect | |
| CN111454375A (en) | Extraction method of tremella polysaccharide | |
| CN102648214A (en) | Method for producing purified hyaluronic acid | |
| CN117586432B (en) | Preparation method and application of zinc hyaluronate | |
| CN108003252A (en) | It is a kind of that there is sea grass polysaccharide carboxy methylation modified outcome for improving antioxidation activity and preparation method thereof | |
| CN112608394A (en) | Preparation method and application of chlorella polysaccharide derivative | |
| CN102599190B (en) | Preparation method of hemicelluloses-based antibacterial antioxidant | |
| CN103948611B (en) | The application of oligoguluronic acid salt in preparation control Parkinson's disease medicine or goods | |
| CN101225126A (en) | A method for extracting chitin and chitin | |
| CN113876996B (en) | Medical hemostatic material and preparation method thereof | |
| CN110123826B (en) | A blueberry anthocyanin-chitooligosaccharide complex and its preparation method and application | |
| CN116585403A (en) | Preparation process and method of selenium-containing eye protection liquid | |
| CN115895291A (en) | Bright monascus yellow pigment and preparation method and application thereof | |
| CN113980149A (en) | Dendrobium huoshanense polysaccharide nano-selenium and preparation method thereof | |
| CN116655825B (en) | Copper hyaluronate and preparation method and application thereof | |
| CN106243243A (en) | A kind of hyaluronic acid purifying technique | |
| CN113876706B (en) | Anthocyanin suspension eye drops and preparation method thereof | |
| CN111888295A (en) | Plant-source antioxidant bacteriostatic environment-friendly hand sanitizer and preparation method thereof | |
| CN116035940B (en) | Antioxidant collagen peptide and preparation method thereof | |
| CN119219993B (en) | A self-assembled supramolecular modified chitosan composite material and its preparation method and application | |
| CN119523864B (en) | Burdock root fermented liquid, preparation method thereof and application thereof in cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |